Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma

Cancer Treatment Reviews

Volumn 33, Issue 3, 2007, Pages 289-298

  Zalatnai, A ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Molecular targeted therapies; Pancreatic cancer; Review

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOSTATIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMC C 225; LAPATINIB; MARIMASTAT; MATUZUMAB; OXALIPLATIN; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 11577; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM PERFORATION; EXTRACELLULAR MATRIX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC CODE; HUMAN; HYPERTENSION; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PNEUMONIA; PROGNOSIS; PROTEIN DETERMINATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; HORMONE ANTAGONISTS; HORMONES; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34249067928     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.12.003     Document Type: Review

References (118)

1. Li D., Xie K., Wolff R., et al. Pancreatic cancer. Lancet 363 9414 (2004) 1049-1057
2. Linder S., Bostrom L., and Nilsson B. Pancreatic cancer in Sweden 1980-2000: a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies. J Gastrointest Surg 10 5 (2006) 672-678
3. Cress R.D., Yin D., Clarke L., et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 17 4 (2006) 403-409
4. Matsuno S., Egawa S., Fukuyama S., et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28 3 (2004) 219-230
5. Smeenk H.G., Tran T.C., Erdmann J., et al. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?. Langenbecks Arch Surg 390 2 (2005) 94-103
6. Schafer M., Mullhaupt B., and Clavien P.A. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 236 2 (2002) 137-148
7. Burris H., and Storniolo A.M. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33 Suppl. 1 (1997) S18-S22
8. Hidalgo M., Castellano D., Paz-Ares L., et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17 2 (1999) 585-592
9. Crino L., Mosconi A.M., Calandri C., et al. Gemcitabine in advanced pancreatic cancer: a phase II trial. Am J Clin Oncol 24 3 (2001) 296-298
10. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60 1 (2001) 8-18
11. Eckel F., Schmelz R., Erdmann J., et al. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest 21 5 (2003) 690-694
12. Meyer F., Grote R., Lippert H., et al. Marginal effects of regional intra-arterial chemotherapy as an alternative treatment option in advanced pancreatic carcinoma. Langenbecks Arch Surg 389 1 (2004) 32-39
13. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 12 (2004) 1200-1210
14. Gower Jr. W.R., Risch R.M., Godellas C.V., et al. HPAC, a new glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol Anim 30A 3 (1994) 151-161
15. Robertson J.F., Watson S.A., and Hardcastle J.D. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int J Cancer 63 1 (1995) 69-75
16. Davies N., Kapur P., Gillespie J., et al. Transforming growth factor α is trophic to pancreatic cancer in vivo. Gut 34 8 (1993) 1097-1098
17. Chester J.F., Gaissert H.A., Ross J.S., et al. Pancreatic cancer in the Syrian golden hamster induced by N-Nitrosobis(2-oxopropyl)amine: cocarcinogenic effect of epidermal growth factor. Cancer Res 46 6 (1986) 2954-2957
18. Yamanaka Y., Friess H., Kobrin M.S., et al. Coexpression of epidermal growth factor receptor ad ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13 3 (1993) 565-569
19. Dong M., Nio Y., Guo K.J., et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 18 6B (1998) 4613-4619
20. Birk D., Gansauge F., Gansauge S., et al. Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 25 2 (1999) 89-96
21. Zalatnai A. Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study. Pathol Oncol Res 5 2 (1999) 146-151
22. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6 5 (2000) 1936-1948
23. Overholser J.P., Prewett M.C., Hooper A.T., et al. Epidermal growth factor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89 1 (2000) 74-82
24. Huang Z.Q., Buchsmaum D.J., Raisch K.P., et al. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 111 2 (2003) 274-283
25. Arnoletti J.P., Buchsmaum D.J., Huang Z.Q., et al. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 8 8 (2004) 960-969
26. Needle M.N. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 29 Suppl 14 (2002) 55-60
27. Xiong H.Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 13 (2004) 2610-2616
28. Krempien R., Muenter M.W., Huber P.E., et al. Randomized phase II - study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283]. BMC Cancer 5 (2005) 131
29. Graeven U., Kremer B., Sudhoff T., et al. Phase I study of the humanized anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94 9 (2006) 1293-1299
30. Grunwald V., and Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 30 3, Suppl. 6 (2003) 23-31
31. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 23 16 Suppl (2005) 1a
32. Hochster H.S., Haller D.G., de Gramont A., et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107 4 (2006) 676-685
33. Sezgin C., Karabulut B., Uslu R., et al. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol 40 12 (2005) 1486-1492
34. Iannitti D., Dipetrillo T., Akerman P., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28 6 (2005) 570-575
35. Li J., Kleeff J., Giese N., et al. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 25 1 (2004) 203-210
36. Rosetti M., Tesei A., Ulivi P., et al. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol Ther 4 10 (2005) 1089-1095
37. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24 4 (2006) 656-662
38. Bruell D., Stocker M., Huhn M., et al. The recombinant anti-EGF receptor immunotoxin 425 (scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23 4 (2003) 1179-1186
39. Bruell D., Bruns C.J., Yezhelyev M., et al. Recombinant anti-EGFR immunotoxin 425 (scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 15 2 (2005) 305-313
40. Yamanaka Y., Friess H., Kobrin M.S., et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24 10 (1993) 1127-1134
41. Lei S., Appert H.E., Nakata B., et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 17 1 (1995) 15-21
42. Day J.D., Digiuseppe J.A., Yeo C., et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27 2 (1996) 119-124
43. Dugan M.C., Dergham S.T., Kucway R., et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 14 3 (1997) 229-236
44. Saxby A.J., Nielsen A., Scarlett C.J., et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29 9 (2005) 1125-1134
45. Büchler P., Reber H.A., Büchler M.C., et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 5 2 (2001) 139-146
46. Büchler P., Reber H.A., Eibl G., et al. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 27 4 (2005) 1125-1130
47. Kimura K., Sawada T., Komatsu M., et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12 16 (2006) 4925-4932
48. Safran H., Iannitti D., Ramanathan R., et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22 5 (2004) 706-712
49. Bruns C.J., Solorzano C.C., Harbison M.T., et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60 11 (2000) 2926-2935
50. Solorzano C.C., Baker C.H., Tsan R., et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 7 8 (2001) 2563-2572
51. Baker C.H., Solorzano C.C., and Fidler I.J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62 7 (2002) 1996-2003
52. Hoekstra R., Dumez H., Eskens F.A., et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 11 19 Pt 1 (2005) 6908-6915
53. Khan A.W., Dhillon A.P., Hutchins R., et al. Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur J Surg Oncol 28 6 (2002) 637-644
54. Takagi K., Takada T., and Amano H. A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer. J Gastroenterol 40 4 (2005) 402-408
55. Niedergethmann M., Hildenbrand R., Wostbrock B., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25 2 (2002) 122-129
56. Seo Y., Baba H., Fukuda T., et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 10 (2000) 2239-2245
57. Bruckner H.W., Hrehorovich V.R., and Sawhney H.S. Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer. Anticancer Res 25 5 (2005) 3637-3639
58. de Gramont A., and Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 Suppl 3 (2005) 46-56
59. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 31 (2005) 8033-8040
60. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 7 (2006) 1145-1151
61. Traxler P., Allegrini P.R., Brandt R., et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64 14 (2004) 4931-4941
62. Yokoi K., Kim S.J., Thaker P., et al. Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 7 7 (2005) 696-704
63. Yokoi K., Sasaki T., Bucana C.D., et al. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65 22 (2005) 10371-10380
64. Zalatnai A. Molecular aspects of stromal - parenchymal interactions in malignant neoplasms. Current Mol Med 6 6 (2006) 685-693
65. Marimastat: BB 2516, TA 2516. Drugs R D 2003;4(3):198-203.
66. Rosemurgy A., Harris J., Langleben A., et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 22 3 (1999) 247-252
67. Bramhall S.R., Rosemurgy A., Brown P.D., et al. Marimastat as a first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19 15 (2001) 3447-3455
68. Bramhall S.R., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 2 (2002) 161-167
69. Molina M.A., Sitja-Arnau M., Lemoine M.G., et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by non-steroidal anti-inflammatory drugs. Cancer Res 59 17 (1999) 4356-4362
70. Okami J., Yamamoto H., Fujiwara Y., et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5 8 (1999) 2018-2024
71. Ding X.Z., Tong W.G., and Adrian T.E. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 20 4 (2000) 2625-2631
72. Crane C.H., Mason K., Janjan N.A., et al. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol 26 4 (2003) S81-S84
73. Milella M., Gelibter A., Di Cosimo S., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 1 (2004) 133-138
74. Ferrari V., Valcamonico F., Amoroso V., et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 57 2 (2006) 185-190
75. El-Rayes B.F., Zalupski M.M., Shields A.F., et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 23 6 (2005) 583-590
76. Eibl G., Takata Y., Boros L.G., et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 65 3 (2005) 982-990
77. Ali S., El-Rayes B.F., Sarkar F.H., et al. Simultaneous targeting of epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4 12 (2005) 1943-1951
78. Cohen S.J., Ranganathan S., Abbruzzese J.L., et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21 7 (2003) 1301-1306
79. Macdonald J.S., McCoy S., Whitehead R.P., et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 23 5 (2005) 485-487
80. Caponigro F., Casale M., and Bryce J. Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs 12 6 (2003) 943-954
81. Ryan D.P., Eder Jr. J.P., Puchlaski T., et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 10 7 (2004) 2222-2230
82. Mirza A.M., Gysin S., Malek N., et al. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 24 24 (2004) 10868-10881
83. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30 5 Suppl 16 (2003) 105-116
84. Lorusso P.M., Adjei A.A., Varterasian M., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23 23 (2005) 5281-5293
85. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 22 (2004) 4456-4462
86. Li L., Aggarwal B.B., Shishodia S., et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcurim (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 10 (2004) 2351-2362
87. Hidaka H., Ishiko T., Furuhashi T., et al. Curcumin inhibits interleukin-8 production and enhances interleukin-8 receptor expression on the cell surface: impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer 95 6 (2002) 1206-1214
88. Lev-Ari S., Zinger H., Kazanov D., et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59 Suppl 2 (2005) S276-S280
89. Li L., Braiteh F.S., and Kurzrock R.L. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104 6 (2005) 1322-1331
90. Alberts S.R., Schroeder M., Erlichman C., et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 22 24 (2004) 4944-4950
91. Harrison L.E., Blumberg D., Berman R., et al. Effect of human growth hormone on human pancreatic carcinoma growth, protein, and cell cycle kinetics. J Surg Res 61 2 (1996) 317-322
92. Fisher W.E., Boros L.G., and Schirmer W.J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 63 1 (1996) 310-313
93. Ohlsson B., Fredang N., and Axelson J. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines. Scand J Gastroenterol 34 12 (1999) 1224-1229
94. Douziech N., Lajas A., Coulombe Z., et al. Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Endocrine 9 2 (1998) 171-183
95. Iwase K., Evers B.M., Hellmich M.R., et al. Inhibition of neurotensine-induced pancreatic carcinoma growth by a nonpeptide neurotensine receptor antagonist, SR48692. Cancer 79 9 (1997) 1787-1793
96. Smith J.P., Verderame M.F., and Zagon I.S. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett 135 1 (1999) 107-112
97. Gastrin 17 vaccine - Aphton: Anti-gastrin 17 immunogen, G17DT: BioDrugs 2003;17(3):223-5.
98. Watson S.A., and Gilliam A.D. G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther 1 2 (2001) 309-317
99. Takhar A.S., Gilliam A.D., Watson S.A., et al. The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur J Surg Oncol 32 2 (2006) 197-200
100. Brett B.T., Smith S.C., Bouvier C.V., et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 20 20 (2002) 4225-4231
101. Chau I., Cunningham D., Russell C., et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomized controlled trials. Br J Cancer 94 8 (2006) 1107-1115
102. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Therap 102 1 (2004) 61-85
103. Klijn J.G., Hoff A.M., Planting A.S., et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62 4 (1990) 627-630
104. Friess H., Büchler M., Ebert M., et al. Treatment of advanced pancreatic cancer with high dose octreotide. Int J Pancreatol 14 3 (1993) 290-291
105. Rosenberg L. Pancreatic cancer: does octreotide offer any promise?. Chemotherapy 47 Suppl 2 (2001) 134-149
106. Rosenberg L., Barkun A.N., Denis M.H., et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of pancreas. Cancer 75 1 (1995) 23-28
107. Wenger F.A., Zieren H.U., and Jacobi C.A. Hormontherapie des postoperativ rezidivierten Pankreas-karzinoms mit Octreotid und Tamoxifen. Langenbeck Arch Chir Suppl Kongressbd 115 (1998) 1348-1350
108. Eckel F., Lersch C., Lippl F., et al. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. J Exp Clin Cancer Res 19 3 (2000) 295-300
109. Tomao S., Romiti A., Massidda B., et al. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res 22 4 (2002) 2361-2364
110. Gordon J.N., Trebble T.M., Ellis R.D., et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54 4 (2005) 540-545
111. Yeung B.H., Huang D.C., and Sinicrope F.A. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 281 17 (2006) 11923-11932
112. Nawrocki S.T., Sweeney-Gotsch B., Takamori R., et al. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3 1 (2004) 59-70
113. Shah M.H., Young D., Kindler H.L., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10 18 Pt 1 (2004) 6111-6118
114. Alberts S.R., Foster N.R., Morton R.F., et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 16 10 (2005) 1654-1661
115. Moore Jr. D.F., Pazdur R., Sugarman S., et al. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. Am J Clin Oncol 18 6 (1995) 525-527
116. Brembeck F.H., Schoppmeyer K., Leupold U., et al. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 83 11 (1998) 2317-2323
117. Riecken E.O., and Rosewicz S. Retinoids in pancreatic cancer. Ann Oncol 10 Suppl 4 (1999) 197-200
118. Recchia F., Sica G., Casucci D., et al. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. Am J Clin Oncol 21 3 (1998) 275-278